Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.
Scott
Phillip A
PA
Department of Emergency Medicine, University of Michigan, Ann Arbor, USA. phlsctt@med.umich.edu
Frederiksen
Shirley M
SM
Kalbfleisch
John D
JD
Xu
Zhenzhen
Z
Meurer
William J
WJ
Caveney
Angela F
AF
Sandretto
Annette
A
Holden
Ann B
AB
Haan
Mary N
MN
Hoeffner
Ellen G
EG
Ansari
Sameer A
SA
Lambert
David P
DP
Jaggi
Michael
M
Barsan
William G
WG
Silbergleit
Robert
R
D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care / Q000379:methods* / Q000592:standards*; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000401:mortality; D015331:Cohort Studies; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D004635:Emergency Medicine / Q000592:standards; D004636:Emergency Service, Hospital; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008824:Michigan / Q000453:epidemiology; D008875:Middle Aged; D016017:Odds Ratio; D017410:Practice Guidelines as Topic; D011379:Prognosis; D016016:Proportional Hazards Models; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator